1446P Preliminary efficacy and safety of rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-pretreated advanced/metastatic non-small-cell lung cancer (NSCLC): ARTEMIDE-01

Mariana Brandão, J.T.J.N. Hiltermann, Els Wauters, Benjamin Solomon, Eduardo Castañón Álvarez, Enriqueta Felip, Eelke Gort, Hiroki Izumi, Dongwook Kim, L. Paz-Ares, Kristoffer Staal Rohrberg, L. Steinbusch, Tatsuya Yoshida, H. Chen, Steve Colebrook, Ikbel Achour, Makoto Origuchi, Francesca Aroldi, Byoung Chul Cho